树突状细胞对裸鼠结肠癌移植瘤的抗癌效应  

Effect of anti-transplanted tumor in nude mice by DC induced in vitro

作　　者：贺子彪[1] 杨伟明[1] 焦保庭[1] 宋辉[1] 

机构地区：[1]遵义医学院附属医院普外科,贵州遵义563003

出　　处：《西安交通大学学报（医学版）》2009年第1期60-62,共3页Journal of Xi’an Jiaotong University（Medical Sciences）

基　　金：贵州省科技基金资助项目[No.(2003)3040]~~

摘　　要：目的研究结肠癌患者外周血树突状细胞(DC)体外诱导后在裸鼠体内的抗癌效应。方法通过皮下移植法建立裸鼠模型,按治疗次数分为对照组、治疗组和加强组;从患者外周血中分离并培养出DC,以肿瘤抗原和金黄色葡萄球菌肠毒素B(SEB)刺激DC;DC激活同源T淋巴细胞;DC激活的T淋巴细胞经用该患者结肠腺癌细胞建立的裸鼠模型的尾静脉注入,观察成瘤时间、肿瘤生长情况、移植肿瘤大小及裸鼠摄食、活动状况。结果成功建立结肠癌裸鼠模型。肿瘤接种第60天,对照组、治疗组及加强组肿瘤大小分别为(3899±22)mm3、(1301±16)mm3、(392±18)mm3。与对照组相比,治疗组及加强组移植瘤生长均受到抑制(P=0.000);与治疗组相比,加强组移植瘤生长抑制更明显(P=0.000)。结论同源结肠癌患者外周血DC和T淋巴细胞共孵后能抑制裸鼠体内移植瘤的生长。这有可能为肿瘤治疗提供一种新的方法。Objective To study the immune response of dendritic cells （DC） modified with tumor antigen and SEB to transplanted tumor in nude mice. Methods Nude mice models were established with human colon cancer cells inoculated subcutaneously, grouped into control group, therapy group and retherapy group; DC was isolated and purified from PBMC of colon carcinoma patient to activate T lymphocyte with DC modified by tumour antigen and SEB. The T lymphocyte was implanted to the models to inhibit the growth of implanted tumor through tail vein. Tumor formation, growth and size, nude mice feeding and activity status were observed. Results The subcutaneously xenotransplanted tumor model of human colon carcinoma in nude mice was successfully established. After colon cancer cells had been inoculated in nude mice for 60 days, volume of transplanted tumor in the control group was （3 899±22）mm^3 , therapy group （1 301±16）mm^3 , and retherapy group （392±18）mm^3. Compared with the control group, the tumor in therapy group and retherapy group could grow slowly （P = 0. 000）. Compared with that in the therapy group, the tumor growth in retherapy group became obviously slower （P=0. 000）. Conclusion The immune response induced by DC can inhibit the growth of transplanted tumor in nudes mice, which may provide a new therapy for tumor.

关 键 词：树突细胞 结肠癌 免疫疗法 裸鼠 抗癌 

分 类 号：R392.12[医药卫生—免疫学]